Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283634 · ClinicalTrials.gov registry record · Phase 2
A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00283634 is a Phase 2 study that was terminated before completion, run by Millennium Pharmaceuticals.
The verdict
NCT00283634, a Phase 2 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
Tarceva, an orally available small molecule, has demonstrated potent activity in tumor models and humans. This randomized, open-label phase 2 study of Tarceva alone and of Tarceva plus VELCADE is designed primarily to determine the objective tumor response rates to these treatments in patients with Stage IIIB or Stage IV non-small cell lung cancer (NSCLC) that is refractory to or has relapsed after front-line chemotherapy.
Interventions
- DRUG erlotinib and bortezomib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-08 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283634
The ClinicalTrials.gov registry entry for NCT00283634 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which erlotinib and bortezomib is the first listed.
NCT00283634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283634 about?
NCT00283634 is a clinical study titled "A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer". Tarceva, an orally available small molecule, has demonstrated potent activity in tumor models and humans. This randomized, open-label phase 2 study of Tarceva alone and of Tarceva plus VELCADE is designed primarily to determine the objective tumor response rates to these treatments in patients with ...
What is the current status of trial NCT00283634?
This trial is currently terminated. It is a Phase 2 study. The study started on 2005-08. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00283634?
The interventions under investigation include: erlotinib and bortezomib (DRUG).
Who is sponsoring clinical trial NCT00283634?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.